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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “is 
frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation via 
colonoscopic versus nasogastric tube administration in treating adults with Clostridium difficile 
infection?” 
 
STUDY DESIGN: Review of two randomized, controlled trials (RCTs) and one randomized, 
open-label, controlled pilot study published between 2014 and 2017. Each included study was 
published in a peer reviewed journal in English language.  
 
DATA SOURCES: Two RCTs and one pilot study were researched via PubMed.  
 
OUTCOMES MEASURED: Resolution of Clostridium difficile infection (CDI) was measured 
via written subject diaries of symptoms for adverse events, stool pattern and CDI episodes. 
Clinical resolution of diarrhea was measured via structural questionnaires and written subject 
diaries of discomfort, bowel movements and stool type using the Bristol Stool Chart, total 
number of bowel movements per 24-hour period, abdominal discomfort and intolerance to 
treatment, and weekly communication after the last fecal microbiota transplant.  
 
RESULTS: The RCT by Lee, et al. showed a statistically significant resolution of diarrhea 
without relapse at 13 weeks and adverse events with frozen fecal microbiota transplantation 
(FMT) (P=0.01). The RCT by Jiang, et al. did not show a statistically significant resolution of 
CDI during the 5 months after transplant with frozen FMT versus fresh FMT (P=0.233). The 
pilot study by Youngster, et al. did not show a statistically significant clinical resolution of 
diarrhea without relapse after 8 weeks with nasogastric versus colonoscopic administration of 
frozen fecal microbiota (P=0.628). 
 
CONCLUSION: The evidence to determine whether frozen FMT is as effective as fresh FMT 
administered via NGT versus colonoscopy in treating adults with CDI is conflicting. The RCT 
by Lee, et al. provided adequate evidence that frozen FMT is non-inferior to fresh FMT at 
inducing clinical resolution of diarrhea in CDI. However, the RCT by Jiang, et al. did not reach 
statistical significance, thus, further investigation is warranted to adequately determine the 
effectiveness of frozen FMT at treating CDI. The administration of frozen FMT via nasogastric 
tube also requires further investigation as Youngster, et al. demonstrated a lack of statistical 
significance compared to colonoscopic administration of frozen FMT.  
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INTRODUCTION 
 Clostridium difficile infection (CDI) is one of the most common causes of nosocomial 
infectious colitis and is frequently associated with antibiotic therapy. Historically CDI has been 
more prevalent amongst the elderly, hospitalized and long-term care patient populations; 
however, the epidemiology is rapidly evolving and previously low risk populations such as the 
antibiotic-naïve and those without recent healthcare encounters are being impacted.1 The severity 
of symptoms of CDI can range from mild abdominal discomfort, cramping and lose stools to 
hematochezia, continuous diarrhea and severe dehydration requiring hospitalization and prompt 
medicinal intervention. CDI is associated with significant and rising morbidity and mortality, as 
well as life-threatening complications including pseudomembranous colitis, bowel perforations, 
toxic megacolon and sepsis. CDI has become a growing medical concern as recurrence rates are 
on the rise with greater than 60% of patients experiencing relapse after initial infection, 
indicating that patients are failing conventional antibiotic therapy.2 
Based on data from 2008 and 2009, there were 349,000 and 336,600 CDI-related hospital 
admissions in the US, respectively.1 CDI-related admissions accounted for nearly 1% of total 
hospital admissions in 2009, and 92% of these admissions were patients >65 years of age.1 In 
2015 in the United States alone, the mean financial burden of a patient hospitalized due to CDI 
was $21,448 and the annual total cost attributable to CDI was 6.3 billion dollars.3 The annual 
hospital management and inpatient treatment of CDI in 2015 amounted to approximately 2.4 
million total days of inpatient stay.3 The exploration of alternative treatment options is 
imperative to improving both the financial and healthcare associated burdens that have risen as 
CDI has evolved in terms of treatment resistance, recurrence and epidemiologic impact.  
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Clostridium difficile is an anaerobic, gram-positive bacillus that is the primary causative 
agent of pseudomembranous colitis and antibiotic-associated diarrhea known as CDI. Within the 
last 15 years, the US incidence of CDI has tripled.4 Patients most likely to be hospitalized for 
CDI are females 85 years of age and older. While CDI was once viewed as a medically 
manageable complication of antimicrobial therapy, it has reemerged in the twenty-first century 
as a potentially refractory, severe infectious disease.1 Usage of broad spectrum antibiotics such as 
ampicillin, clindamycin, fluoroquinolones and third generation cephalosporins are associated 
with a higher risk of CDI. A healthy gastrointestinal tract consists of a diverse microbial gut 
biome that serves as a defense mechanism against pathogenic microbes. Although antimicrobial 
therapy ideally wipes out pathogenic organisms, CDI can result as the ability of indigenous 
microbes to prevent the colonization of pathogenic organisms such as C. difficile may be 
impeded.  
Ironically, the first line treatment for CDI is antibiotic administration aimed to prevent 
further growth of C. difficile and improve symptoms. Based on the recently updated 
IDSA/SHEA guidelines, oral vancomycin or fidaxomicin should be utilized as gold standard 
therapy for CDI regardless of severity.6 In mild to moderate CDI when neither of these 
antibiotics are available or are contraindicated oral metronidazole may be used. Patients who 
experience recurrent or refractory CDI are often treated with prolonged oral vancomycin tapers. 
An alternative treatment to antibiotic therapy for recurrent CDI is FMT. While CDI alters the 
colonic microbiota, FMT can replenish the normal gut flora without prolonged antibiotic therapy 
and its subsequent side effects.  Fresh and frozen fecal products obtained from qualified donors 
and administered by the upper and lower GI tracts are being explored as curative treatments for 
recurrent and refractory CDI. This paper utilizes two randomized controlled trials (RCTs) and 
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one randomized, controlled pilot study to evaluate the effectiveness of both frozen versus fresh 
fecal microbiota transplantation (FMT) and FMT delivered via nasogastric versus colonoscopic 
administration at treating CDI. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “is frozen fecal 
microbiota transplantation as effective as fresh fecal microbiota transplantation via colonoscopic 
versus nasogastric tube administration in treating adults with Clostridium difficile infection?” 
METHODS 
 The studies included in this review are two randomized, controlled trials and one 
randomized, open-label, controlled pilot study. The populations of interest were adults over the 
age of 18 years old with recurrent or refractory CDI. The interventions being evaluated were 
frozen FMT and frozen FMT administered via nasogastric tube (NGT) compared against fresh 
FMT and frozen FMT administered via colonoscopy. The outcomes measured in these studies 
were clinical resolution of diarrhea without relapse after 8 weeks, resolution of CDI, and clinical 
resolution of diarrhea without relapse at 13 weeks and adverse events. The key words utilized in 
the data source search were fecal microbiota transplant and clostridium difficile.  
Each of the included articles were published in peer reviewed journals in English language. The 
articles were researched via PubMed and selected based on their ability to answer my proposed 
clinical question with results measured in terms of patient oriented outcomes (POEMs). 
Inclusion criteria required that the studies be randomized, controlled and published within the 
last 10 years. Studies were excluded if the majority of participants were under the age of 18 years 
old. The summary of statistics reported include both NNT and p-value.   
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Table 1 – Demographics of Included Studies 
 
OUTCOMES MEASURED  
 Youngster, et al.4 addressed clinical resolution of diarrhea without relapse after 8 weeks 
which was defined as less than 3 bowel movements per 24 hours. Patients were followed with 
structural questionnaires administered on days 1, 2, 3, 7, 14, and 21, and at 2 and 6 months after 
the procedure (primarily by phone). Questionnaires recorded stool frequency and consistency, 
general well-being on a standardized health score, rating of gastrointestinal symptoms, 
Study Type # 
of 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Youngster 
(2014) (4) 
Randomized, 
open-label, 
controlled 
pilot study 
20 58.6 
+ 
19.6 
Refractory or 
recurrent CDI: 
relapse of CDI 
after >3 
episodes mild-
moderate CDI 
and failure of 
6-8 week 
taper with 
vancomycin 
OR >2 
episodes of 
severe CDI 
resulting in 
hospitalization 
and associated 
with 
significant 
morbidity 
Anatomic CI 
to NGT or 
colonoscopy, 
delayed 
gastric 
emptying 
syndrome, 
recurrent 
aspirations, 
pregnancy, 
significantly 
compromised 
immunity, 
history of 
significant 
allergy to 
foods not 
excluded from 
donor diet 
0 Frozen fecal 
microbiota 
transplantation 
administered via 
nasogastric tube 
(NGT) 
Jiang (2017) 
(5) 
RCT 73 33-
88 
History of > 3 
separate bouts 
of CDI in past 
12 months in 
nonpregnant 
adults > 18 
years of age 
Previous 
recipient of a 
fecal 
microbiota 
transplant 
1 Frozen fecal 
microbiota 
transplantation 
Lee (2016) (2) RCT 232 72.2 
+ 
15.9 
Pts 18 years 
or older with 
history of 
recurrent or 
refractory 
CDI 
Neutropenia, 
peripheral 
WBC counts 
> 30.0 x 
109/L, or toxic 
megacolon 
25 Frozen fecal 
microbiota 
transplantation 
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medication use, and weight changes, and elicited possible adverse events by use of a 
modification of the Common Terminology Criteria for Adverse Events version 3.0 approved by 
the FDA and institutional review board. Jiang, et al.5 measured resolution of CDI with cure 
defined as freedom from bouts of CDI during the 5 months after FMT. Patients kept written 
subject diaries of symptoms at regular intervals for 5 months after FMT for adverse events, stool 
pattern and CDI episodes. Lee, et al.2 addressed clinical resolution of diarrhea without relapse at 
13 weeks and adverse events by patient diaries that recorded discomfort, bowel movements and 
stool type using the Bristol Stool Chart. Patients were instructed to record the total number of 
bowel movements per 24-hour period, abdominal discomfort and intolerance to treatment 
between days 1 and 12. Weekly communication was maintained after the last FMT to evaluate 
any evidence of recurrence or adverse events.  
   RESULTS 
 Within 6 academic medical centers in Canada, Lee, et al.2 assessed the eligibility of 263 
patients who were 18 years or older with histories of refractory or recurrent CDI, excluding those 
who met exclusion criteria. Utilizing a computer-generated random number system 232 patients 
were then assigned to receive either fresh or frozen FMT delivered via enema (114 to receive 
frozen and 118 to receive fresh). Only 108 and 111 of the patients randomized to the frozen and 
fresh groups respectively received the enemas as randomized, which formed a modified intention 
to treat (mITT) population. The mITT population included all patients who were lost to follow-
up, received one FMT but required antibiotic therapy afterwards, received both types of FMT or 
required antibiotic therapy for additional infections. The per-protocol population of 91 and 87 
patients randomized to frozen and fresh groups respectively consisted of patients who received 
two FMTs of the same type, did not receive antibiotic therapy between enemas and did not 
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require antibiotic therapy for additional infections. For the evaluation purposes of this review the 
per-protocol population was utilized.   
To ensure that the study remained double-blind the enemas were prepared by an 
unblinded laboratory technician. The patients received 50 mL of either fresh or frozen FMT via 
enema on day 1 and those whose CDI showed no signs of improvement by day 4 received a 
second enema between days 5 to 8. Patients nonresponsive to both FMT enemas were considered 
treatment failures and offered a third enema or antibiotic therapy. The primary clinical outcome 
addressed was clinical resolution of diarrhea without relapse at 13 weeks and adverse events. 
Within the per-protocol population, 76 of 91 (83.5%) in the frozen FMT and 74 of 87 (85.1%) in 
the fresh FMT fulfilled the primary outcome, demonstrating that frozen FMT was non-inferior to 
fresh FMT (95% CI -10.5-∞; P=0.01). RBI, ABI and NNT are calculated in Table 2. The most 
common adverse events (AEs) during the follow-up period were constipation (20%) and 
excessive flatulence (25%), without any difference in proportion of these events between the two 
groups. Serious adverse events (SAEs) were defined as a life-threatening event, death, new or 
prolonged hospitalization or newly developed significant impact on daily activities. At the 13-
week follow-up, 29 SAEs occurred although none were found to be attributable to the FMT 
based on blinded investigation. In total 4 patients died from unresolved CDI, 2 in each the fresh 
and frozen groups. Refer to Table 3 for AEs and SAEs due to FMT. 
Youngster, et al.4 studied 20 patients aged 7-90 years old with refractory or recurrent CDI 
as defined by inclusion criteria who were recruited via referral from colleagues at Massachusetts 
General Hospital. A computer-generated randomization system was utilized to assign patients to 
treatment arms to evaluate the effectiveness of frozen FMT delivered via nasogastric versus 
colonoscopic administration; however, as an open-label study both the patients and investigators 
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were aware of the treatments being administered. The 10 patients allocated to colonoscopic 
frozen FMT group completed standard bowel preparation and received 90 cc thawed fecal 
product in the right colon, as well as one dose of Loperamide to promote product retention. 
Forty-eight hours prior to the procedure, the 10 patients in the NGT frozen FMT group were 
administered 2 mg/kg/day of omeprazole, and then received 90 cc of thawed fecal product via 
appropriately sized NGT. Patients who exhibited no signs of improvement in both arms were 
offered a second FMT via route of administration of their choice. All 20 patients received the 
treatments they were randomized to and no patients were lost to follow-up.  
   The primary clinical outcome addressed was clinical resolution of diarrhea without 
relapse within 8 weeks of follow-up. Follow-up for those who received a second FMT began the 
day of the second administration, thus, all clinical outcomes were measured according to the 
intention-to-treat analysis. All statistical tests were considered two sided with a P-value of <0.05 
indicating statistical significance and categorical variables were compared using the Fisher exact 
test. After the first administration of FMT, 6 of 10 (60%) patients in the NGT group met the 
primary outcome, compared to 8 of 10 (80%) in the colonoscopy group (P=0.628). One patient in 
the original NGT group denied a second FMT, while the remaining 5 received frozen FMT via 
NGT. After the second FMT all four patients from the original colonoscopy group met the 
primary outcome, resulting in a 10 of 10 (100%) cure rate compared to 8 of 10 (80%) in the NGT 
group (P=0.53). RBI, ABI and NNT are calculated in Table 2. Of the two patients who failed 
treatment, one refused further FMT administration and the other was later discovered to have 
been self-administering homemade fecal enemas daily the week prior to the study. AEs 
associated with the FMT such as abdominal discomfort and bloating were experienced by 4 of 20 
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patients (20%). None of the SAEs that occurred were found to be related to the FMT by 
investigators (Table 3).  
Jiang, et al.5 assessed 73 patients 18 years of age or older who met inclusion criteria to 
evaluate the effectiveness of fresh versus frozen FMT delivered by colonoscopy at a single out-
patient clinic in Houston, Texas. Randomization was utilized to assign 25 patients to both the 
fresh and frozen FMT groups, although one patient in the frozen microbiota group was lost to 
follow-up. To maintain double-blinding the laboratory director was the only individual aware of 
the product assignments. Each of the patients completed standard bowel preparation the night 
prior to receiving the allocated FMT via colonoscopy performed by two gastroenterologists. The 
fecal product was delivered half in the proximal colon with the remainder infused progressively 
throughout the colon to the rectum.  
The primary outcome measured was resolution of CDI. Although cure was defined as 
freedom from bouts of CDI at 5 months, the initial follow-up was completed after 2 months. At 
the two-month follow-up, 20 of 24 (83%) who received frozen FMT obtained resolution, 
compared to 25 of 25 (100%) in the fresh FMT group (CI 1.37-405.42; P=0.233). RBI, ABI and 
NNT are calculated in Table 2. According to the study there were no SAEs and the proportion of 
AEs between the two groups was equal. Within the first 2 days following FMT the most 
common AEs were nausea, mild diarrhea and abdominal discomfort (86%). It should be noted 
that the breakdown of AEs amongst the treatment arms included the use of lyophilized FMT that 
was not utilized for the purposes of this review and the percentage of AEs is skewed to include 
this population of patients (Table 3).  
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Table 2 – Calculations for Treatment from Lee, et al.2, Youngster, et al.4, and Jiang, et al.5 
Study CER EER RBI ABI NNT P-value 
Lee, et al. 0.851 0.835 -0.019 -0.016 -63 0.01 
Youngster, et al. 0.80 0.60 -0.25 -0.20 -5 0.628 
Jiang, et al. 1.00 0.83 -0.17 -0.17 -6 0.233 
 
Table 3 – AEs/SAEs related to FMT from Lee, et al.2, Youngster, et al.4, and Jiang, et al.5  
Study Adverse Events (AEs) Serious Adverse Events (SAEs) 
Lee, et al. Fresh/Frozen: Constipation (20%)  
Excessive Flatulence (25%) 
Frozen FMT: 2% 
Fresh FMT: 2% 
Youngster, et al. Fresh/Frozen: Abdominal 
Discomfort, Bloating (20%) 
None 
Jiang, et al.  NGT/Colonoscopy: Nausea, 
Abdominal Discomfort, Mild 
Diarrhea (86%) 
None 
 
DISCUSSION  
 Lee, et al.2 demonstrated statistical significance supporting that frozen enema FMT is 
non-inferior to fresh enema FMT at inducing clinical resolution of diarrhea within 13 weeks in 
patients suffering from refractory or recurrent CDI. However, Jiang, et al.5 did not exhibit 
statistical significance indicating that frozen FMT was not as effective at curing CDI as fresh 
FMT delivered via colonoscopy. The varying routes of administration of the FMT products in 
these studies cannot be ignored as a factor that could have impacted the effectiveness of the FMT 
and makes direct comparison of the outcomes less applicable. Although the results of Youngster, 
et al.4 did not support that NGT administration of frozen FMT was as effective as colonoscopy 
based on lack of statistical significance, the study did indicate that clinical resolution of diarrhea 
without relapse after 8 weeks was more likely to be achieved with additional FMTs. While the 
mean age of patients in this study was 54 years old, all three pediatric patients that were included 
Summers, Fecal Microbiota Transplant and CDI 10 
received clinical cure after one administration of FMT, emphasizing the need for further 
investigation into the effectiveness of FMT in pediatric patients with CDI. 
 Numerous contraindications to FMT exist and must be evaluated to ensure patient safety 
and the prevention of undesired clinical outcomes. Patients in whom FMT is contraindicated are 
those who are pregnant, diagnosed with toxic megacolon or have anatomic abnormalities that 
could impact the delivery method. 7 In patients who cannot tolerate the anesthesia or bowel 
preparation required for colonoscopic administration NGT could be a viable option, which 
emphasizes the importance of further studies to determine its effectiveness. Each of these modes 
of delivery has associated risks that must also be weighed, such as aspiration with NGT and 
bowel perforation with colonoscopy.  
Insurance coverage of FMT as a treatment for recurrent or refractory CDI is dependent 
upon the patient’s ability to satisfy specific coverage criteria. If these criteria are met, most 
insurance companies offer coverage pending that the FMT is deemed medically necessary and 
not performed for experimental purposes. These criteria prolong the infectious process of CDI as 
patients must experience numerous recurrences or increased severity of episodes before coverage 
becomes available. The term ‘coverage’ also becomes ambiguous as insurance companies are not 
required to include the testing of donor stool, a medically necessary step to ensure that the fecal 
product is safe prior to administration.8 Due to the risk of transmission of numerous infectious 
diseases including HIV, donor screening and stool sample testing are imperative to ensure the 
efficacy and safety of this treatment modality.  
  A major limitation to this search was the lack of RCTs utilizing the same interventions 
and comparisons in regard to FMT as a treatment for CDI. This made direct comparison of the 
results amongst these studies less reliable, as numerous confounding variables, primarily routes 
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of administration, exist amongst them. A limitation to the studies completed by Lee, et al. and 
Jiang, et al. was the limited follow-up at 13 and 8 weeks respectively, which are both insufficient 
time frames to properly evaluate the long-term efficacy and safety of FMT. To address the 
unknown long-term safety Lee, et al. is performing a 10-year follow-up on the patients in the 
study to evaluate the long-term positive and negative outcomes. The use of enemas to deliver 
FMT was another limitation of Lee, et al. as the effectiveness of enemas compared to other 
delivery methods must be evaluated in further studies. The notably small sample sizes in the 
trials performed by Youngster, et al. and Jiang, et al. also served as limitations.  
CONCLUSION 
 The evidence to determine whether frozen FMT is as effective as fresh FMT 
administered via NGT versus colonoscopy in treating adults with CDI is conflicting. While Lee, 
et al. concluded that frozen FMT was non-inferior to fresh FMT, Jiang, et al. did not determine 
statistical significance between the two. Thus, additional studies are warranted to effectively 
evaluate both types of fecal products administered by the same route to determine which is 
superior in the utilization of FMT as a treatment for CDI. The effects of stool donors on FMT 
must also be further explored, as the donor selections within these three studies varied and 
introduced another area for future research. While NGT administration was not deemed 
statistically significant, its overall effectiveness was enforced by the 100% cure rate achieved in 
the colonoscopy group after a second NGT FMT administration. Studies with significant 
prolonged follow-up are necessary to determine the long-term outcomes associated with FMT. 
With the information provided by future studies a standard of care will be established to govern 
FMT and help to propel the most effective form of this treatment modality to the forefront in 
patients suffering from recurrent and refractory CDI.
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